The global nucleic acid labelling market was valued at USD 1925 million in 2023. The global nucleic acid labelling market is expected to have a 8.65 % CAGR from 2024 to 2032 and be worth USD 4061.61 million by 2032 from USD 2091.51 million in 2024.
Nucleic Acid Labelling has many applications in the fields of drug discovery and identification of new diseases. Nucleic acids are large complex molecules that carry genetic information. Two major types of nucleic acids are DNA and RNA. DNA has the forward function of hereditary characteristics to next-generation, while RNA carries protein synthesis. Nucleic acids are labeled with tags that facilitate the detection and purification process. Many methods involve chemicals and enzymes for labeling nucleic acids like a corporation of fluorescent tags, radioactive phosphates, and modifications with biotin, which are primarily for biotechnology applications.
The rise in investments in research and development centers to introduce new products is the key driving factor for growth. Increasing focus on genomics is propelling the demand of the market. Using this genome analysis, scientists can customize drugs to make them more effective, thereby improving treatment outcomes. Besides, this approach can be used to detect and diagnose diseases in a particular way by categorizing them by genetic variation rather than symptoms, thereby attracting large numbers of patients to it, which in turn boosts the nucleic acid labeling market.
Initiatives by public and private organizations are accelerating the growth of the nucleic acid labelling market. The increasing prevalence of the design of synthetic genomes through different technologies available in the biotechnology field is solely to fuel the demand of the market. Increasing support from the government by changing schemes in favor of ordinary people to present growth opportunities for the market players. Growing disposable income is also one more factor leveraging the demand of the market. Furthermore, the market is led by shifting people's interest in personalized medicine.
The growing incidence of chronic diseases directing to diabetes and other cardiovascular diseases and patient demand for personalized drugs is one of the primary drivers of the nucleic acid labeling market during the forecast period. With the remarkable development of sequencing technology, various species' genome, from bacteria to humans, has been completely sequenced. Besides, the sequencing speed has been dramatically accelerated by the recent advent of Next Generation Sequencing (NGS) methods, which previously followed conventional capillary sequencing methods. NGS methods analyze different sizes and types of DNA libraries in a more precise, fast, and inexpensive way and in a generalized way, driving the market. NGS provides powerful tools for not only discovering critical biological information such as whole genome sequences, DNA protein variations, and interactions but is also applicable for diagnostic and clinical uses, thus helping your market to grow.
However, the government's stringent rules and regulations in approving newly manufactured reference products are limiting the growth of the market. The lack of skilled persons to monitor the procedures is also restricting the demand of the market. The cost of installing and maintaining overall equipment is a bit high, and it remained a challenging thing for the market developers. The lack of qualified professionals is a significant setback to the growth of the nucleic acid labeling market during the forecast period. Additionally, due to the lack of a qualified professional to understand the interpretation of HCV test results, when more specific tests should be performed and which test should be considered for this purpose.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2023 to 2032 |
Segments Covered |
By Product, Labelling Technique, Application, End-User and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Based on product type, the reagents and kits segment held the major share of the worldwide market in 2023 and is anticipated to grow at a notable CAGR during the forecast period owing to the growing scale of diagnostic centers with the latest devices, increasing aging population and rise in the incidences of various health disorders.
Based on the labeling technique, the PCR labeling technique had the largest share of the global market in 2023 and is expected to grow at a healthy CAGR during the forecast period owing to the increasing number of healthcare centers and promising to elevate patient care by reducing the cost for treatment services.
Based on the application, the DNA sequencing segment accounted for a dominating share of the worldwide market in 2023 and is anticipated to grow promisingly during the forecast period owing to the growing patient population suffering from genetic diseases.
Based on end-user, the research centers segment captured the major share of the market in 2023 and is expected to grow notably during the forecast period owing to the increasing government funding to increase research activity and drug discovery.
Geographically, the North American region had the major share of the global nucleic acid labelling market in 2023 and the domination of the regional market is expected to continue during the forecast period owing to the rapid adoption of the latest technologies. The growing R&D activities around genomics is a significant driver of the North American nucleic acid labelling market. Increasing the adoption of personalized healthcare technology is one of the key drivers of market development during the forecast period. The growth of personalized medicine and the identification of genetically engineered and therapeutic areas by the growth of the North American region. The morbidity of chronic diseases such as cancer, the aging population, the increasing demand for targeted, personalized medicine, and the growing efforts of the government in the North American region are surging the growth of the market to the extent. In recent years, the government has initiated several efforts to supplement the development of the North American nucleic acid labelling market.
The Asia Pacific and Europe are next to North America in leading dominant shares with the rise in revenue in almost every country and increasing benefits over early diagnosis processes. The Middle East and Africa will have substantial growth opportunities in the coming years.
Some of the key market participants playing a promising role in the Global Nucleic Acid Labelling Market profiled in this report are Thermo Fisher Scientific, New England Biolabs, PerkinElmer, F. Hoffmann La-Roche AG, General Electric Company, Merck KGaA, Enzo Biochem, Promega Corporation, Vector Laboratories, and Agilent Technologies.
By Product
By Labelling Technique
By End-Users
By Region
Frequently Asked Questions
The global nucleic acid labelling market was worth USD 1925 million in 2023.
The growing demand for molecular diagnostics, growing research in genomics and proteomics, and increasing investments in life sciences research are majolry propelling the growth of the nucleic acid labelling market.
Thermo Fisher Scientific, Merck KGaA, Promega Corporation, GE Healthcare, and Agilent Technologies are some of the major players in the nucleic acid labelling market.
Some of the challenges faced by the nucleic acid labelling market include the high cost of labelling reagents and instruments, the complexity of labelling procedures, and the increasing demand for alternative labelling methods.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region